|Articles|December 15, 2004

Pat Survey

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

A top view of medicine powders, liquids in containers, and various manufactured medicine on the American flag. An America pharmaceuticals concept. | image Credit: ©Ming -stock.adobe.com

The FDA Moves to Modernize Drug Manufacturing Registration

BySusan Haigney

July 10th 2026

Sarclisa Escena is subcutaneous injection designed for 3 multiple myeloma treatment combinations

The Implications of Isatuximab-irfc’s FDA Approval for Multiple Myeloma

ByZachary Zubulake

July 10th 2026

PharmTech Weekly Roundup–July 10, 2026

BySusan Haigney

July 10th 2026

Regulatory Actions Impacting Biologics

BySiegfried Schmitt,Susan J. Schniepp

July 9th 2026

Teva Pharmaceutical Industries and Polpharma Biologics Collab on Ocrevus (ocrelizumab)

What the Ocrelizumab Deal Does for the Multiple Sclerosis Biosimilar Pipeline

ByZachary Zubulake

July 9th 2026

Pat Survey

Related Content

The FDA Moves to Modernize Drug Manufacturing Registration

The Implications of Isatuximab-irfc’s FDA Approval for Multiple Myeloma

PharmTech Weekly Roundup–July 10, 2026

Regulatory Actions Impacting Biologics

What the Ocrelizumab Deal Does for the Multiple Sclerosis Biosimilar Pipeline

Trending on Pharmaceutical Technology

What the Ocrelizumab Deal Does for the Multiple Sclerosis Biosimilar Pipeline

The Implications of Isatuximab-irfc’s FDA Approval for Multiple Myeloma

The Next Generation of Medicine: Personalized, Preventive, and Powered by Technology

What FDA's AI Warning Letter Tells Us About GMP Accountability

The FDA Moves to Modernize Drug Manufacturing Registration